Traction does not decrease failure of reduction and femoral head avascular necrosis in patients aged 6-24 months with

Yi-Qiang Li1, Ming Li2, Yue-Ming Guo3

  • 1Department of Pediatric Orthopaedics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou.

Insights

Preliminary traction does not improve outcomes for developmental dysplasia of the hip. This study found no significant reduction in failed reductions or avascular necrosis (AVN) rates when traction was used before closed reduction in infants.

Area of Science:

  • Orthopedic surgery
  • Pediatric orthopedics
  • Developmental dysplasia of the hip treatment

Background:

  • Developmental dysplasia of the hip (DDH) is a common condition in infants.
  • Late-detected DDH often requires closed reduction.
  • Preliminary traction is a debated adjunct to closed reduction for DDH.

Purpose of the Study:

  • To evaluate the impact of preliminary traction on closed reduction success.
  • To assess the effect of preliminary traction on avascular necrosis (AVN) incidence in DDH.
  • To compare radiographic outcomes between traction and no-traction groups for DDH.

Main Methods:

  • Retrospective study of 385 patients (440 hips) with late-detected DDH treated by closed reduction.
  • Patients divided into traction (276) and no-traction (109) groups.
  • Radiographic assessment including Tönnis grade, reduction failure, AVN, acetabular index, center-edge angle, and Severin's grade; meta-analysis performed.

Main Results:

  • No significant difference in failure of reduction rates between traction (9.2%) and no-traction (5.6%) groups (P=0.203).
  • Similar avascular necrosis (AVN) rates: 14% in traction group vs. 14.5% in no-traction group (P=0.881).
  • Meta-analysis confirmed no significant difference in AVN rates with or without preliminary traction (OR=0.76, P=0.32).

Conclusions:

  • Preliminary traction does not reduce the failure of reduction in DDH treated by closed reduction.
  • Preliminary traction does not decrease the incidence of avascular necrosis (AVN) in DDH.
  • Radiographic outcomes were comparable between groups, suggesting traction is not essential for these cases.

Related Concept Videos

Oxidation-Reduction Reactions03:11

Oxidation-Reduction Reactions

Oxidation–Reduction Reactions
75.7K
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
236
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
701
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
261
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
215
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
253